Rapid Acting Antidepressants: Emerging Treatments for Major Depressive Disorder

View Activity

FACULTY

Program Chair
Joseph F. Goldberg, MD

Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
Department of Psychiatry
New York, NY

PROGRAM OVERVIEW

This case-based activity will cover the treatment and management of patients with major depressive disorder (MDD).

TARGET AUDIENCE

This activity is intended for psychiatrists, nurse practitioners, and physician assistants, involved in the care of patients with major depressive disorder.

LEARNING OBJECTIVES

Upon completion of the CME activity, learners should be better able to:

  • Discuss the role of novel neurotransmitter system dysregulation and synaptic plasticity in the etiology of MDD
  • Describe the mechanism of action and pharmacodynamics of NMDA modulators
  • Review the efficacy and safety profiles of emerging therapies targeting the NDMA receptor in patients with MDD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent for their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment and management of patients with MDD.

CNE Credits:
1.0 ANCC Contact Hour(s)

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Goldberg has received royalties from American Psychiatric Publishing, Inc. He is on the speakers’ bureaus for Allergan, Neurocrine, Otsuka, Sunovion, and Takeda- Lundbeck. Dr. Goldberg is a consultant for Lundbeck, Neurocrine, and Otsuka.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Chris Drury, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Melissa Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, Dr. Goldberg may mention the use of medications for both FDA-approved and non-approved indications

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Submit the evaluation form.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: June 3, 2019

EXPIRATION DATE: June 3, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.